These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 14606349)

  • 1. [Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status].
    Tieleman RG
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2046-8. PubMed ID: 14606349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R; Tran M; Gore JM; Spencer FA
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ximelagatran: a new oral anticoagulant.
    Francis CW
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):139-52. PubMed ID: 15171963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ximelagatran in prevention of cardiovascular events.
    Molckovsky D; Boucher M
    Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran: direct thrombin inhibitor.
    Ho SJ; Brighton TA
    Vasc Health Risk Manag; 2006; 2(1):49-58. PubMed ID: 17319469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics.
    Ezekowitz MD
    Am Heart Hosp J; 2004; 2(4 Suppl 1):31-5. PubMed ID: 15539973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ximelagatran: a promising new drug for oral anticoagulation].
    Scardi S; Giansante C
    Monaldi Arch Chest Dis; 2004 Mar; 62(1):34-9. PubMed ID: 15211735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.